|Dr. Athena Maria Countouriotis||Pres, CEO & Director||897.1k||N/A||1972|
|Dr. Jingrong Jean Cui Ph.D.||Co-Founder, Consultant & Director||641.9k||N/A||1964|
|Mr. Brian L. Baker CPA, M.S., MS, CPA||VP of Fin. & Admin.||316.39k||N/A||1967|
|Ms. Yi Larson||Exec. VP & CFO||N/A||N/A||1980|
|Dr. Siegfried Reich||Exec. VP & Chief Scientific Officer||N/A||N/A||1960|
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.
Turning Point Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.